GlassScriptPhysician profile
Retna Billano
NPI 1033208541
$14,468.05
in general payments reported to CMS, 2019-2025
33 companies · $939 in 2025
The $939 reported for 2025 was more than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,441 · 2020: $1,418 · 2021: $2,733 · 2022: $2,896 · 2023: $2,592 · 2024: $1,449 · 2025: $939.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,972 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,972.00 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,916.46 | 2019-2025 | Skyrizi, Botox, Rinvoq |
| Merz North America, INC. | $2,841.89 | 2019-2025 | Xeomin |
| Allergan, INC. | $2,138.53 | 2019-2022 | |
| Janssen Biotech, INC. | $697.54 | 2020-2024 | Tremfya, Remicade, Simponi |
| Regeneron Healthcare Solutions, INC. | $683.82 | 2019-2025 | Dupixent |
| Incyte Corporation | $570.86 | 2021-2025 | Opzelura |
| Pfizer INC. | $531.27 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $515.63 | 2019-2025 | |
| Leo Pharma INC. | $501.69 | 2019-2023 | Adbry |
| Galderma Laboratories, L.P. | $491.84 | 2019-2025 | Aklief, Nemluvio, Oracea |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $383.97 | 2019-2024 | Arazlo, Jublia, Cabtreo |
| Lilly USA, LLC | $328.77 | 2019-2025 | Taltz, Ebglyss |
| Dermavant Sciences, INC. | $294.40 | 2022-2024 | Vtama |
| Genzyme Corporation | $276.08 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $194.14 | 2019-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $176.74 | 2022-2024 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $158.65 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $90.33 | 2024-2025 | |
| Epi Health, LLC | $83.31 | 2019-2022 | |
| Almirall LLC | $78.69 | 2019-2021 | |
| Prugen, INC. Pharmaceuticals | $75.88 | 2019 | |
| Vyne Pharmaceuticals INC. | $74.87 | 2021 | |
| Aclaris Therapeutics, INC. | $74.28 | 2019 | |
| Medimetriks Pharmaceuticals, INC. | $57.33 | 2019 | |
| Organon LLC | $53.46 | 2025 | |
| Verrica Pharmaceuticals INC. | $37.06 | 2023 | Ycanth |
| Dermira, INC. | $29.44 | 2019 | |
| Mission Pharmacal Company | $28.28 | 2019 | |
| Sandoz INC. | $22.05 | 2020 | |
| Amgen INC. | $18.41 | 2025 | Otezla |
| Encore Dermatology INC. | $15.27 | 2020 | |
| Celgene Corporation | $14.59 | 2019 | |
| Merck Sharp & Dohme LLC | $12.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Retna Billano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.